Table 3 Synergy of drug combinations.

Drug 1 (EC₅₀^a)	Drug 2 (EC₅₀^a)	HCC1806		HCC1806 + HA-CREB3L1
Drug 1 (EC₅₀^a)	Drug 2 (EC₅₀^a)	ZIP^b (drug1; drug2)	% Cytotoxicity	ZIP^b (drug1; drug2)	% Cytotoxicity
Palbociclib Isethionate (500 nM)	Doxorubicin (13.2 nM)	12.4 (37 nM; 1.37 nM)	50	5.1 (111 nM; 0.08 nM)	26
Palbociclib Isethionate (500 nM)	Paclitaxel (1.2 nM)	6.6 (492 nM; 0.46 nM)	50	8.7 (9000 mM; 1.2 nM)	95
Cladribine (92 nM)	Doxorubicin (13.2 nM)	16.2 (12 nM; 1.37 nM)	21	18.8 (37 nM; 4.12 nM)	24
Cladribine (92 nM)	Paclitaxel (1.2 nM)	9.3 (12 nM; 0.15 nM)	15	24 (79 nM; 0.46 nM)	41
Lanatoside C (143 nM)	Doxorubicin (13.2 nM)	1.3 (31 nM; 111 nM)	55	9.1 (31 nM; 4.12 nM)	17
Lanatoside C (143 nM)	Paclitaxel (1.2 nM)	2.8 (16 nM; 111 nM)	96	12 (151 nM; 0.46 nM)	53
Homoharringtonine (29 nM)	Doxorubicin (13.2 nM)	15.7 (12 nM; 0.46 nM)	21	12.7 (12 nM; 1.37 nM)	14
Homoharringtonine (29 nM)	Paclitaxel (1.2 nM)	51 (12 nM; 0.15 nM)	76	59 (12 nM; 0.15 nM)	83

Quick links

Search